Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

被引：0
|
作者：
Strober, Bruce [1 ,2 ]
Paul, Carle [3 ]
Blauvelt, Andrew [4 ]
Thaci, Diamant [5 ]
Elewski, Boni [6 ]
White, Katy [7 ]
Vanvoorden, Veerle [7 ]
Deherder, Delphine [7 ]
Staelens, Fabienne [7 ]
Spelman, Lynda [8 ]
Eyerich, Kilian [9 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Cent Connecticut Dermatol Res, Cromwell, CT USA
[3] Paul Sabatier Univ, Toulouse, France
[4] Oregon Med Res Ctr, Portland, OR USA
[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH 44106 USA
[7] UCB Pharma, Brussels, Belgium
[8] Verac Clin Res, Woolloongabba, Qld, Australia
[9] Tech Univ Munich, Munich, Germany
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of briakinumab for treatment of moderate to severe psoriasis in patients previously receiving etanercept: Results from an open-label extension
    Strober, Bruce
    Leonardi, Craig
    Williams, David A.
    Olds, Michele
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB191 - AB191
  • [32] Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
    Paller, Amy S.
    Hong, Ying
    Becker, Emily M.
    de Lucas, Raul
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Barcellona, Claire
    Maes, Peter
    Fiorillo, Loretta
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 389 - 397
  • [33] Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: Results of an open-label phase IIIB multicenter trial
    Menter, A
    Hamilton, T
    Papp, K
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P195 - P195
  • [34] Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial
    Warren, Richard B.
    Strober, Bruce
    Lebwohl, Mark
    Foley, Peter
    Langley, Richard G.
    Davis, Leah
    Hoepken, Bengt
    Szilagyi, Balint
    Ciaravino, Valerie
    Bewley, Anthony
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [35] Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
    McKevitt, N.
    Rich, P.
    Langley, R. G.
    Menter, A.
    Krueger, G.
    Zhu, B.
    Wei, H.
    Cameron, G. S.
    Heffernan, M. P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 50 - 50
  • [36] EFFICACY AND SAFETY OF 108 WEEKS' BIMEKIZUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: INTERIM RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY
    Mcinnes, I.
    Merola, J. F.
    Mease, P. J.
    Coates, L. C.
    Joshi, P.
    Coarse, J.
    Ink, B.
    Ritchlin, C. T.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1149 - 1150
  • [37] Efficacy and Safety of 108 Weeks of Bimekizumab Treatment in Patients with Psoriatic Arthritis: Interim Results from a Phase 2 Open-Label Extension Study
    McInnes, I. B.
    Merola, J. F.
    Mease, P. J.
    Coates, L. C.
    Schmitz, N.
    Joshi, P.
    Coarse, J.
    Ink, B.
    Ritchlin, C. T.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 8S
  • [38] Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis
    Papp, Kim
    Leonardi, Craig
    Gordon, Kenneth
    Frevert, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB193 - AB193
  • [39] Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years An Open-Label Extension of Randomized Clinical Trials
    Armstrong, April W.
    Lebwohl, Mark
    Warren, Richard B.
    Sofen, Howard
    Imafuku, Shinichi
    Ohtsuki, Mamitaro
    Spelman, Lynda
    Passeron, Thierry
    Papp, Kim A.
    Kisa, Renata M.
    Vaile, John
    Berger, Victoria
    Vritzali, Eleni
    Hoyt, Kim
    Colombo, Matthew J.
    Scotto, Julie
    Banerjee, Subhashis
    Strober, Bruce
    Thaci, Diamant
    Blauvelt, Andrew
    JAMA DERMATOLOGY, 2025, 161 (01) : 56 - 66
  • [40] BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS
    Merola, J. F.
    Gottlieb, A. B.
    Morita, A.
    Carrascosa, J. M.
    Elewski, B.
    Tilt, N.
    Wiegratz, S.
    Wixted, K.
    Mrowietz, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1766 - 1767
12345